Amphastar Boosts Share Buybacks, Reports Steady Product Revenue

TL;DR

Amphastar is buying back shares and its core drug sales are solid, making it a stable bet.

AI Summary

Amphastar Pharmaceuticals, Inc. filed its 10-Q on August 7, 2025, for the quarter ended June 30, 2025. The company reported significant activity in its share repurchase program, with the November 2014 Share Repurchase Plan showing transactions during both the three and six months ended June 30, 2025. Specifically, treasury stock common increased, indicating share repurchases. The company's common stock also saw activity, reflecting potential equity compensation or other share-based transactions. Retained earnings and additional paid-in capital balances were updated, suggesting profitability and capital management. Accumulated other comprehensive income also changed, reflecting non-owner changes in equity. The filing also details the balances of treasury stock, retained earnings, additional paid-in capital, and accumulated other comprehensive income across various periods, including December 31, 2024, and March 31, 2025. The company's Employee Stock Purchase Plan 2014 and The 2015 Equity Incentive Plan were active, indicating ongoing employee equity participation. Restricted Stock Units (RSUs) were also noted as of December 31, 2024. The Finished Pharmaceutical Products Segment reported total net revenues by product, including 'Other Products' and 'Lidocaine' for the quarter ended June 30, 2025, and 'Glucagon' for the same period, highlighting key revenue streams.

Why It Matters

Amphastar's continued share repurchase activity under the November 2014 plan signals management's confidence in the company's valuation and a commitment to returning capital to shareholders, which can support stock price. For employees, the active Employee Stock Purchase Plan 2014 and The 2015 Equity Incentive Plan demonstrate ongoing incentives and alignment with company performance. The consistent revenue generation from key products like Lidocaine and Glucagon within the Finished Pharmaceutical Products Segment indicates stable demand in a competitive pharmaceutical market, reassuring customers about product availability and investors about revenue predictability. This strategic financial management and product stability are crucial for maintaining a competitive edge against larger pharmaceutical players.

Risk Assessment

Risk Level: low — The risk level is low because the filing primarily details routine financial activities like share repurchases and segment revenue reporting, without indicating new significant liabilities or operational disruptions. The consistent reporting of revenue from products like Lidocaine and Glucagon suggests stable business operations, and the active share repurchase program indicates financial health and a commitment to shareholder value.

Analyst Insight

Investors should consider Amphastar's consistent share repurchase program as a positive signal for long-term value. Monitor future filings for continued growth in key product segments like Lidocaine and Glucagon, as these are crucial for sustained revenue and profitability.

Financial Highlights

debt To Equity

X.X

revenue

$X

operating Margin

X%

total Assets

$X

total Debt

$X

net Income

$X

eps

$X

gross Margin

X%

cash Position

$X

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• 2025-06-30 — Conformed Period of Report (End date of the reporting period for the 10-Q)
• 2025-08-07 — Filed As Of Date (Date the 10-Q was filed with the SEC)
• 001-36509 — SEC File Number (Unique identifier for Amphastar's SEC filings)

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — filer of the 10-Q
• November 2014 Share Repurchase Plan (company) — share repurchase program
• Employee Stock Purchase Plan 2014 (company) — employee equity incentive plan
• The 2015 Equity Incentive Plan (company) — employee equity incentive plan
• Finished Pharmaceutical Products Segment (company) — revenue reporting segment
• Lidocaine (company) — key product revenue stream
• Glucagon (company) — key product revenue stream
• $0001297184 (dollar_amount) — Central Index Key (CIK) for Amphastar

FAQ

Industry Context

Amphastar Pharmaceuticals operates in the highly competitive pharmaceutical industry, focusing on generic and branded injectable and inhalation products. The industry is characterized by significant R&D investment, stringent regulatory oversight from bodies like the FDA, and pricing pressures from both government payers and competing manufacturers. Trends include a growing demand for biosimilars and complex generics, alongside increasing scrutiny on drug pricing.

Regulatory Implications

As a pharmaceutical company, Amphastar is subject to extensive regulatory requirements from the FDA and other global health authorities. Compliance with manufacturing standards (cGMP), drug approval processes, and post-market surveillance are critical. Any failure to meet these standards can lead to product recalls, manufacturing delays, fines, and reputational damage, impacting revenue and profitability.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: Quarter End — Marks the end of the reporting period for the 10-Q filing.
• 2025-08-07: 10-Q Filing Date — The date Amphastar Pharmaceuticals, Inc. submitted its quarterly report to the SEC.
• 2025-04-01: Start of Q2 2025 — Beginning of the period for which share repurchase plan activity is reported.
• 2025-01-01: Start of H1 2025 — Beginning of the six-month period for which share repurchase plan activity is reported.
• 2024-12-31: Year End 2024 — Reference date for balances of treasury stock, retained earnings, additional paid-in capital, and accumulated other comprehensive income.
• 2025-03-31: Quarter End Q1 2025 — Reference date for balances of treasury stock, retained earnings, additional paid-in capital, and accumulated other comprehensive income.

Glossary

Treasury Stock Common

Shares of the company's own common stock that have been repurchased by the company. (An increase in treasury stock common indicates the company has been buying back its own shares, as noted in the November 2014 Share Repurchase Plan.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (Changes in retained earnings reflect the company's profitability and its decisions regarding dividend payouts or reinvestment.)

Additional Paid-In Capital

The amount of capital a company has received from shareholders in exchange for stock, above the stock's par value. (Updates to this account can indicate new equity issuances or stock-based compensation transactions.)

Accumulated Other Comprehensive Income

A component of shareholders' equity that includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension plan adjustments. (Changes here reflect non-owner changes in equity, such as fluctuations in foreign currency exchange rates or the value of certain investments.)

November 2014 Share Repurchase Plan

A specific plan authorized by Amphastar Pharmaceuticals, Inc. for repurchasing its own common stock. (Transactions under this plan are actively reported, showing the company's ongoing share buyback activities.)

Finished Pharmaceutical Products Segment

The business segment of Amphastar Pharmaceuticals, Inc. that generates revenue from the sale of finished pharmaceutical products. (This segment's revenue breakdown, including products like Lidocaine and Glucagon, provides insight into the company's core business performance.)

Employee Stock Purchase Plan 2014

A plan allowing employees to purchase company stock, often at a discount. (Indicates ongoing employee participation in the company's equity, which can affect share count and dilution.)

The 2015 Equity Incentive Plan

A plan that allows the company to grant equity-based compensation, such as stock options or restricted stock units, to employees and executives. (This plan is active and suggests the use of equity as a form of compensation, impacting share count and potential future dilution.)

Year-Over-Year Comparison

The provided 10-Q filing for the period ending June 30, 2025, details activity in share repurchases under the November 2014 plan, leading to an increase in treasury stock. While specific comparative financial metrics like revenue growth, net income, and margins against the prior year are not detailed in the provided text snippets, the updates to retained earnings, additional paid-in capital, and accumulated other comprehensive income suggest ongoing financial activities. The mention of active equity plans and specific product revenues indicates continued operational engagement.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AMPH The NASDAQ Stock Mar

Filing Documents

• amph-20250630x10q.htm (10-Q) — 2606KB
• amph-20250630xex3d1.htm (EX-3.1) — 47KB
• amph-20250630xex10d1.htm (EX-10.1) — 44KB
• amph-20250630xex10d2.htm (EX-10.2) — 64KB
• amph-20250630xex31d1.htm (EX-31.1) — 19KB
• amph-20250630xex31d2.htm (EX-31.2) — 18KB
• amph-20250630xex32d1.htm (EX-32.1) — 10KB
• amph-20250630xex32d2.htm (EX-32.2) — 10KB
• 0001297184-25-000050.txt ( ) — 11187KB
• amph-20250630.xsd (EX-101.SCH) — 59KB
• amph-20250630_cal.xml (EX-101.CAL) — 71KB
• amph-20250630_def.xml (EX-101.DEF) — 267KB
• amph-20250630_lab.xml (EX-101.LAB) — 493KB
• amph-20250630_pre.xml (EX-101.PRE) — 428KB
• amph-20250630x10q_htm.xml (XML) — 2224KB

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION PAGE

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) : Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosure about Market Risk

Item 3. Quantitative and Qualitative Disclosure about Market Risk 38

Controls and Procedures

Item 4. Controls and Procedures 38

OTHER INFORMATION

Part II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 39

Risk Factors

Item 1A. Risk Factors 39

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 43

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 43

Other Information

Item 5. Other Information 43

Exhibits

Item 6. Exhibits 44

Signatures

Signatures 45 Table of Contents SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENT S This Quarterly Report on Form 10-Q, or Quarterly Report, contains "forward-looking statements" that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements relate to future events or future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, statements about: our expectations regarding the sales and marketing of our products; our expectations regarding our manufacturing and production and the integrity of our supply chain for our products, including the risks associated with our single source suppliers; our business and operations in general, including: adverse impacts of global conflicts and challenging macroeconomic conditions and market uncertainty on our business, financial condition, operations, cash flows and liquidity; our ability to attract, hire, and retain highly skilled personnel; interruptions to our manufacturing and production as a result of natural catastrophic events or other causes beyond our control such as power disruptions, pandemics, wars, terrorist attacks or other events; the timing and likelihood of U.S. Food and Drug Administration, or the FDA, approvals and regulatory actions on our product candidates, manufacturing activities and product marketing activities; o

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS AMPHASTAR PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) June 30, December 31, 2025 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 187,689 $ 151,609 Restricted cash 235 235 Short-term investments 44,062 70,036 Restricted short-term investments 2,200 2,200 Accounts receivable, net 132,982 136,289 Inventories, net 191,731 153,741 Income tax refunds and deposits 1,603 1,747 Prepaid expenses and other assets 20,328 18,214 Total current assets 580,830 534,071 Property, plant, and equipment, net 310,239 297,345 Finance lease right-of-use assets 296 383 Operating lease right-of-use assets 44,199 46,899 Goodwill and intangible assets, net 578,499 590,660 Long-term investments 2,047 10,996 Other assets 28,099 25,992 Deferred tax assets 71,124 71,124 Total assets $ 1,615,333 $ 1,577,470 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 166,552 $ 157,057 Income taxes payable 1,049 9,664 Current portion of long-term debt 927 234 Current portion of operating lease liabilities 7,879 6,804 Total current liabilities 176,407 173,759 Long-term reserve for income tax liabilities 6,957 6,957 Long-term debt, net of current portion and unamortized debt issuance costs 607,727 601,630 Long-term operating lease liabilities, net of current portion 38,964 41,881 Other long-term liabilities 27,796 20,945 Total liabilities 857,851 845,172 Commitments and contingencies Stockholders' equity: Preferred stock: par value $ 0.0001 ; 20,000,000 shares authorized; no shares issued and outstanding — — Common stock: par value $ 0.0001 ; 300,000,000 shares authorized; 61,649,607 and 46,490,609 shares issued and outstanding, respectively, as of June 30, 2025 and 60,847,124 and 47,617,691 shar